$Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma$

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. Multicenter, observational, retrospective study in patients with clear-cell mRCC treated wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2017-05, Vol.8 (18), p.30410-30421
Hauptverfasser:	Puente, Javier, Laínez, Nuria, Dueñas, Marta, Méndez-Vidal, María José, Esteban, Emilio, Castellano, Daniel, Martinez-Fernández, Mónica, Basterretxea, Laura, Juan-Fita, María José, Antón, Luis, León, Luis, Lambea, Julio, Pérez-Valderrama, Begoña, Vázquez, Sergio, Suarez, Cristina, Del Muro, Xavier Garcia, Gallardo, Enrique, Maroto, José Pablo, Samaniego, M Luz, Suárez-Paniagua, Beatriz, Sanz, Julián, Paramio, Jesús M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biomarkers, Tumor Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - metabolism Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Drug Resistance, Neoplasm Female Gene Expression Profiling Humans Indoles - administration & dosage Indoles - adverse effects Indoles - therapeutic use Kaplan-Meier Estimate Male MicroRNAs - genetics Molecular Targeted Therapy Neoplasm Staging Prognosis Pyrroles - administration & dosage Pyrroles - adverse effects Pyrroles - therapeutic use Research Paper Retrospective Studies ROC Curve Signal Transduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!